{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:40:35Z","timestamp":1772084435560,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,1,21]],"date-time":"2002-01-21T00:00:00Z","timestamp":1011571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite the current widespread use of prophylactic G\u2010CSF in children with solid tumours and leukaemia, its effectiveness has not been clearly demonstrated. This randomised study evaluates the role of G\u2010CSF given after a 5\u2010day intensification block in children with acute lymphoblastic leukaemia (ALL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Forty\u2010six children with ALL or T\u2010Cell non\u2010Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony\u2010stimulating factor following either the first or the second block of intensive chemotherapy in a cross\u2010over study to determine if the prophylactic administration of G\u2010CSF could reduce the rate of readmission to hospital for management of febrile neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was a statistically significant difference in the rate of hospital admission in the group receiving prophylaxis, with 34 of 46 being admitted, compared to 42 of 46 patients in the control arm (74 vs. 91%; <jats:italic>P<\/jats:italic>\u2009=\u20090.0386). There were no differences found in duration of hospital admission, haematological toxicity, neutrophil recovery or duration of supportive care between the two groups. There was no demonstrable cost benefit derived from the prophylactic administration of G\u2010CSF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study shows that the prophylactic administration of G\u2010CSF following intensification chemotherapy for childhood ALL and T\u2010NHL produces a significant reduction in the rate of readmission to hospital for the management of febrile neutropenia. Med Pediatr Oncol 2002;38:98\u2013103. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mpo.1279","type":"journal-article","created":{"date-parts":[[2004,10,25]],"date-time":"2004-10-25T15:34:20Z","timestamp":1098718460000},"page":"98-103","source":"Crossref","is-referenced-by-count":24,"title":["A randomised study of prophylactic G\u2010CSF following MRC UKALL XI intensification regimen in childhood ALL and T\u2010NHL"],"prefix":"10.1002","volume":"38","author":[{"given":"M.A.","family":"Little","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Morland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Easlea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.R.","family":"Pinkerton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,21]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199305063281808"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90376-Q"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.6.1430.1430"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.6.488"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2471"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1200\/JCO.1997.15.10.3288","article-title":"Update of recommendations for the use of hematopoietic colony\u2010stimulating factors: Evidence\u2010based, clinical practice guidelines","volume":"15","author":"Somerfield MR","year":"1997","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90164-7"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.62.1.12"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1163"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","article-title":"Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer","volume":"13","author":"Chevallier B","year":"1995","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199905)32:5<331::AID-MPO4>3.0.CO;2-M"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706193362503"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood.V87.8.3143.bloodjournal8783143","article-title":"A randomized phase\u2010III study of the efficacy of granulocyte colony\u2010stimulating factor in children with high\u2010risk acute lymphoblastic leukemia","volume":"87","author":"Welte K","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1995.tb01816.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710303371815"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470106"},{"key":"e_1_2_1_19_2","first-page":"395","article-title":"Trial of chemotherapy plus recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor in children with advanced neuroblastoma","volume":"18","author":"Santana VM","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530130310"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1200\/JCO.1998.16.2.522","article-title":"Randomized trial of r\u2010metHu granulocyte colony\u2010stimulating factor in an intensive treatment for T\u2010cell leukemia and advanced\u2010stage lymphoblastic lymphoma of childhood: a pediatric oncology group pilot study","volume":"16","author":"Laver J","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00061-6"},{"key":"e_1_2_1_23_2","first-page":"132","article-title":"A case\u2010control retrospective study of the efficacy of granulocyte colony\u2010stimulating factor in children with neuroblastoma","volume":"16","author":"Housholder SE","year":"1994","journal-title":"Am J Pediatr Hematol\u2010Oncol"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.10.750"},{"key":"e_1_2_1_25_2","first-page":"248","article-title":"Use of rhGM\u2010CSF to reduce the consequences of myelotoxicity in children receiving chemotherapy","volume":"25","author":"Stevens MCG","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950801)76:3<510::AID-CNCR2820760323>3.0.CO;2-W"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.1991.9.6.1022","article-title":"Therapeutic effects and pharmacokinetics of recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy","volume":"9","author":"Furman WL","year":"1991","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950200602"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230403"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.901"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199403000-00006"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019209016587"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.2849.2849"},{"key":"e_1_2_1_34_2","first-page":"162","article-title":"Effects of granulocyte colony\u2010stimulating factor in children with severe neutropenia","volume":"25","author":"Welte K","year":"1994","journal-title":"Acta Haematol Pol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695970"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.444.bloodjournal862444"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.V81.2.561.561","article-title":"No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony\u2010stimulating factor for life\u2010 threatening infection during remission induction and consolidation therapy [2]","volume":"81","author":"Ohno R","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_38_2","first-page":"1026","article-title":"Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukemia","volume":"7","author":"Mirro JJ","year":"1993","journal-title":"Leukemia"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.1279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.1279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:51:25Z","timestamp":1700394685000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.1279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,21]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1002\/mpo.1279"],"URL":"https:\/\/doi.org\/10.1002\/mpo.1279","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,21]]}}}